Stock Events

Stock Events

BridgeBio Pharma 

$77.24
103
-$5.74-6.92% 08:00 Today

Statistics

Day High
82.99
Day Low
82.89
52W High
93.42
52W Low
46.81
Volume
59,364
Avg. Volume
-
Mkt Cap
16.22B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.4
-1.13
-0.85
-0.58
Expected EPS
-0.621211
Actual EPS
N/A

Financials

-144.39%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
502.08MRevenue
-724.93MNet Income

Analyst Ratings

104.38Average Price Target
The highest estimate is 130.00.
From 15 ratings within the last 6 months. This is not an investment recommendation.
Buy
87%
Hold
13%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BBIO. It's not an investment recommendation.
NVIDIA
25
NVDA
Amazon
22
AMZN
Microsoft
20
MSFT
Alphabet
20
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is focused on developing treatments for cystic fibrosis and other genetic diseases, overlapping with BridgeBio's focus on genetic disorders.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the genetic disease space where BridgeBio operates.
Novartis
NVS
Mkt Cap286.78B
Novartis offers treatments for a wide range of diseases, including genetic disorders, making it a competitor in some of BridgeBio's key areas.
Biomarin Pharmaceutical
BMRN
Mkt Cap13.04B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic diseases, directly competing with BridgeBio.
PTC Therapeutics
PTCT
Mkt Cap5.98B
PTC Therapeutics focuses on the discovery and commercialization of novel medicines, including for genetic disorders, competing with BridgeBio.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics for genetic diseases, competing in the same field as BridgeBio.
Sarepta Therapeutics
SRPT
Mkt Cap1.91B
Sarepta Therapeutics is focused on the discovery and development of RNA-based therapeutics for rare diseases, making it a competitor to BridgeBio.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.61B
Ultragenyx Pharmaceutical focuses on rare and ultra-rare genetic diseases, directly competing with BridgeBio in the rare disease market.

About

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Show more...
CEO
Neil Kumar
Employees
839
Country
United States
ISIN
US10806X1028
WKN
000A2PLX7

Listings

XETRA
DE
2CL.XETRA
MI
IT
1BBIO.MI
STU
DE
2CL.STU
F
DE
2CL.F

0 Comments

Share your thoughts

FAQ

What is BridgeBio Pharma stock price today?▼
The current price of BBIO is $77.24 USD — it has decreased by -6.92% in the past 24 hours. Watch BridgeBio Pharma stock price performance more closely on the chart.
What is BridgeBio Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange BridgeBio Pharma stocks are traded under the ticker BBIO.
Is BridgeBio Pharma stock price growing?▼
BBIO stock has fallen by -1.03% compared to the previous week, the month change is a +1.97% rise, over the last year BridgeBio Pharma has showed a +69.66% increase.
What is BridgeBio Pharma market cap?▼
Today BridgeBio Pharma has the market capitalization of 16.22B
When is the next BridgeBio Pharma earnings date?▼
BridgeBio Pharma is going to release the next earnings report on October 29, 2026.
What were BridgeBio Pharma earnings last quarter?▼
BBIO earnings for the last quarter are -0.78 USD per share, whereas the estimation was -0.58 USD resulting in a -35.51% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is BridgeBio Pharma revenue for the last year?▼
BridgeBio Pharma revenue for the last year amounts to 502.08M USD.
What is BridgeBio Pharma net income for the last year?▼
BBIO net income for the last year is -724.93M USD.
How many employees does BridgeBio Pharma have?▼
As of August 19, 2026, the company has 839 employees.
In which sector is BridgeBio Pharma located?▼
BridgeBio Pharma operates in the Health & Wellness sector.
When did BridgeBio Pharma complete a stock split?▼
BridgeBio Pharma has not had any recent stock splits.
Where is BridgeBio Pharma headquartered?▼
BridgeBio Pharma is headquartered in PALO ALTO, United States.